Clinical data | |
---|---|
Trade names | Regumate, Matrix |
Routes of administration |
Oral |
ATCvet code | |
Identifiers | |
|
|
Synonyms | Allyltrenbolone; RU-2267; 17α-Allylestra-4,9,11-trien-17β-ol-3-one; 17α-Allyl-19-nor-δ9,11-testosterone |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.011.549 |
Chemical and physical data | |
Formula | C21H26O2 |
Molar mass | 310.42994 g/mol |
3D model (Jmol) | |
|
|
|
Altrenogest (INN, USAN, BAN) (brand names Regumate, Matrix; former developmental code name RU-2267), also known as allyltrenbolone or allyltrienolone, as well as 17α-allyl-19-nor-δ9,11-testosterone or 17α-allylestra-4,9,11-trien-17β-ol-3-one, is a steroidal progestin of the 19-nortestosterone and allyltestosterone groups related to allylestrenol, norgestrienone, and trenbolone that is widely used in veterinary medicine to suppress or synchronize estrus in horses and pigs. It is available for veterinary use in both Europe (as Regumate) and the United States (as Matrix), and has been marketed as Regumate since the early 1980s.
According to its manufacturer Roussel Uclaf, altrenogest has weak anabolic and androgenic activity equivalent to 1/20th of that of testosterone. However, no significant androgenic effects have been observed in young stallions or mature mares, and altrenogest has notably been used to maintain pregnancy in mares (similarly to the use of allylestrenol to maintain pregnancy in women) with no incidence of virilization or other abnormalities in filly offspring. On the other hand, minor potential anabolic/androgenic effects have been suggested for altrenogest in pigs.